ShuYu Civilian Pharmacy Corp., Ltd. (SHE:301017)
China · Delayed Price · Currency is CNY 13.49
+0.15 (1.12%)
At close: May 8, 2026
SHE:301017 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 10,550 | 10,327 | 9,487 | 9,122 | 7,709 | 5,286 |
Other Revenue | - | - | 83.26 | 69.51 | 114.13 | 35.25 |
| 10,550 | 10,327 | 9,570 | 9,191 | 7,823 | 5,322 | |
Revenue Growth (YoY) | 10.94% | 7.91% | 4.13% | 17.49% | 47.00% | 14.70% |
Cost of Revenue | 7,788 | 7,626 | 7,158 | 6,597 | 5,592 | 3,806 |
Gross Profit | 2,762 | 2,702 | 2,412 | 2,594 | 2,231 | 1,515 |
Selling, General & Admin | 2,538 | 2,465 | 2,392 | 2,259 | 1,812 | 1,330 |
Research & Development | - | - | - | - | 0.05 | - |
Other Operating Expenses | 12.36 | 12.9 | 20.14 | 19.81 | 16.57 | 12.47 |
Operating Expenses | 2,550 | 2,478 | 2,426 | 2,302 | 1,849 | 1,342 |
Operating Income | 211.63 | 223.9 | -13.93 | 291.99 | 381.8 | 173.57 |
Interest Expense | - | - | -138.88 | -118.33 | -73.43 | -31.98 |
Interest & Investment Income | 1.33 | - | 12.23 | 13.79 | 11.18 | 13.56 |
Currency Exchange Gain (Loss) | - | - | 0.02 | -0.01 | - | - |
Other Non Operating Income (Expenses) | -180.73 | -172.92 | -35.58 | -11.96 | -11.95 | -25.34 |
EBT Excluding Unusual Items | 32.55 | 50.99 | -176.14 | 175.5 | 307.59 | 129.8 |
Impairment of Goodwill | - | - | -48.88 | - | - | - |
Gain (Loss) on Sale of Investments | 104.5 | 104.5 | 8.48 | 0.07 | 0.11 | 24.82 |
Gain (Loss) on Sale of Assets | 27.09 | 27.07 | 22.65 | 10.25 | 2.08 | -0.71 |
Asset Writedown | -9.57 | -10.83 | - | - | - | - |
Legal Settlements | - | - | - | -0.61 | - | -9.26 |
Other Unusual Items | - | - | -19.45 | -7.6 | 10.77 | 5.81 |
Pretax Income | 154.58 | 171.73 | -213.34 | 177.59 | 320.55 | 150.46 |
Income Tax Expense | 50.66 | 54.82 | -8.33 | 37.54 | 87.3 | 36.14 |
Earnings From Continuing Operations | 103.92 | 116.91 | -205.01 | 140.05 | 233.24 | 114.32 |
Minority Interest in Earnings | -4.95 | -2.68 | 16.2 | -6.99 | -3.81 | 0.6 |
Net Income | 98.97 | 114.23 | -188.81 | 133.06 | 229.43 | 114.92 |
Net Income to Common | 98.97 | 114.23 | -188.81 | 133.06 | 229.43 | 114.92 |
Net Income Growth | - | - | - | -42.00% | 99.64% | -46.88% |
Shares Outstanding (Basic) | 388 | 408 | 402 | 403 | 403 | 383 |
Shares Outstanding (Diluted) | 388 | 408 | 402 | 403 | 403 | 383 |
Shares Change (YoY) | -7.94% | 1.56% | -0.37% | 0.17% | 5.07% | 4.47% |
EPS (Basic) | 0.26 | 0.28 | -0.47 | 0.33 | 0.57 | 0.30 |
EPS (Diluted) | 0.26 | 0.28 | -0.47 | 0.33 | 0.57 | 0.30 |
EPS Growth | - | - | - | -42.10% | 90.00% | -49.15% |
Free Cash Flow | 615.76 | 630.5 | 315.78 | -38.64 | 37.99 | 100.92 |
Free Cash Flow Per Share | 1.59 | 1.54 | 0.79 | -0.10 | 0.09 | 0.26 |
Dividend Per Share | - | - | - | 0.050 | 0.115 | 0.073 |
Dividend Growth | - | - | - | -56.52% | 57.53% | -33.64% |
Gross Margin | 26.18% | 26.16% | 25.21% | 28.22% | 28.52% | 28.47% |
Operating Margin | 2.01% | 2.17% | -0.15% | 3.18% | 4.88% | 3.26% |
Profit Margin | 0.94% | 1.11% | -1.97% | 1.45% | 2.93% | 2.16% |
Free Cash Flow Margin | 5.84% | 6.11% | 3.30% | -0.42% | 0.49% | 1.90% |
EBITDA | 271.06 | 284.95 | 53.6 | 359.83 | 440.06 | 219.28 |
EBITDA Margin | 2.57% | 2.76% | 0.56% | 3.91% | 5.63% | 4.12% |
D&A For EBITDA | 59.43 | 61.05 | 67.52 | 67.83 | 58.26 | 45.71 |
EBIT | 211.63 | 223.9 | -13.93 | 291.99 | 381.8 | 173.57 |
EBIT Margin | 2.01% | 2.17% | -0.14% | 3.18% | 4.88% | 3.26% |
Effective Tax Rate | 32.77% | 31.92% | - | 21.14% | 27.24% | 24.02% |
Revenue as Reported | - | - | 9,570 | 9,191 | 7,823 | 5,322 |
Advertising Expenses | - | - | 31.8 | 41.64 | 36.79 | 29.62 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.